Berlin Heals Launches Pivotal International Clinical Trial for Heart Failure Treatment
Berlin Heals Initiates C-MIC IV Clinical Trial
Berlin Heals Holding AG, a Swiss medical device company in the clinical phase, has announced the launch of the C-MIC IV international randomized, double-blind, placebo-controlled clinical trial designed to evaluate its pioneering microcurrent therapy for heart failure. This study is built upon the groundwork laid by the previous C-MIC III trial, introducing a more minimally invasive outpatient implantation procedure performed in a catheterization lab.
The C-MIC IV trial marks a significant advancement by being the first double-blind placebo-controlled evaluation of microcurrent therapy, with patients randomly assigned to either an active treatment group or a placebo control group. The trial aims to recruit 60 patients from six European countries: Spain, Belgium, Netherlands, Denmark, Serbia, and Bosnia-Herzegovina. Participants included in the study will present with symptomatic heart failure resulting from either non-ischemic or ischemic causes, with a reduced ejection fraction greater than 20%. This broadens the patient population compared to previous studies, indicating the initiative's ambition to yield more robust clinical evidence.
All trial participants will receive an implantation of the medical devices; however, they will remain unaware of whether their treatment is activated or not. By the conclusion of the C-MIC IV project, Berlin Heals expects to have expanded its clinical experience with microcurrent technology to over 120 patients suffering from heart failure.
The first patient involved in this groundbreaking trial was implanted in Kragujevac, Serbia, under the care of Dr. Miodrag Sreckovic, the head of the Interventional Cardiology Service at the University Clinical Center Kragujevac. "The launch of the C-MIC IV international trial represents a pivotal moment for Berlin Heals as we continue to solidify a solid body of evidence for this novel therapy," stated John Brumfield, CEO of Berlin Heals.
Dr. Faouzi Kallel, the company’s Scientific Director, emphasized, "CMIC-IV is the second randomized trial of microcurrent therapy, characterizing safety and efficacy details to inform the design of our upcoming pivotal IDE trial."
Conducting randomized, double-blind, placebo-controlled trials with implantable medical devices can be challenging due to the need to maintain blinding. Prof. Stefan Anker, a physician at Charité and global principal investigator, noted, "Since microcurrent therapy is not perceived by the patient and treatment allocation can be concealed from evaluating clinicians, CMIC-IV allows us to rigorously assess the therapy using a double-blind, placebo-controlled design."
Founded in 2014, Berlin Heals Holding AG focuses on pioneering cardiac solutions. Its C-MIC technology delivers a constant low-level electrical current to the heart, creating a localized electric field aimed at improving cardiac function. Early clinical results suggest this novel approach may yield early and sustained benefits for patients experiencing chronic heart failure. As this trial progresses, the medical community eagerly anticipates the potential of this innovative therapy to provide new hope for heart failure patients.